Patents by Inventor Jacopo Bonanomi

Jacopo Bonanomi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210179654
    Abstract: The present invention relates to a process for the preparation of Cangrelor in salt form of formula (V) by preparation and subsequent hydrolysis of an intermediate of formula (IV). The process is characterised by the high yield and purity of the product, and can be used industrially.
    Type: Application
    Filed: October 29, 2018
    Publication date: June 17, 2021
    Inventors: Jacopo BONANOMI, Mattia BERTOLOTTI, Barbara NOVO
  • Publication number: 20210171464
    Abstract: Disclosed is the amorphous form of pimavanserin* hemitartrate, the process for its preparation, and pharmaceutical formulations containing it.
    Type: Application
    Filed: October 29, 2018
    Publication date: June 10, 2021
    Inventors: Mattia BERTOLOTTI, Jacopo BONANOMI, Barbara NOVO
  • Publication number: 20210130296
    Abstract: Disclosed is a process for the synthesis of pimavanserin base with a high yield and purity, which comprises: a) converting tert-butyl-N-[(4-propan-2-yloxyphenyl)methyl]carbamate (Formula (I)) to 1-(isocyanatomethyl)-4-propan-2-yloxybenzene of formula (II) b) adding N-[(4-fluorophenyl)methyl]-1-methylpiperidin-4-amine (Formula (IV)) to the solution obtained in a) to give pimavanserin base, and c) purifying the pimavanserin base obtained in step b).
    Type: Application
    Filed: April 24, 2019
    Publication date: May 6, 2021
    Applicant: OLON S.P.A.
    Inventors: Barbara Novo, Jacopo Bonanomi, Mattia Bertolotti
  • Publication number: 20200407355
    Abstract: Disclosed are new crystalline forms of venetoclax, a selective Bcl2 inhibitor used as a chemotherapy agent, and the processes for preparation of said crystalline forms by treating venetoclax with suitable solvents.
    Type: Application
    Filed: February 28, 2019
    Publication date: December 31, 2020
    Applicant: Olon S.P.A.
    Inventors: Barbara Novo, Jacopo Bonanomi, Gaia Migliazza
  • Publication number: 20190276399
    Abstract: Disclosed is a partly crystalline form of nintedanib ethanesulphonate and its preparation process.
    Type: Application
    Filed: June 6, 2017
    Publication date: September 12, 2019
    Applicant: Olon S.P.A.
    Inventors: Barbara Novo, Jacopo Bonanomi, Stella De Fiore, Francesco Calogero
  • Patent number: 9981951
    Abstract: Disclosed are a novel crystalline form and an amorphous form of Olaparib, and the process for their preparation.
    Type: Grant
    Filed: December 19, 2016
    Date of Patent: May 29, 2018
    Assignee: OLON S.P.A.
    Inventors: Barbara Novo, Jacopo Bonanomi, Stella Defiore, Francesco Calogero
  • Patent number: 9828380
    Abstract: Disclosed is a novel process for the synthesis of tofacitinib citrate on an industrial scale with high yields and purity starting with cis-(1-benzyl-4-methyl-piperidin-3-yl)methylamine bis-hydrochloride racemate (intermediate VIII), which comprises: 1. Condensation between intermediates VII and VIII to give intermediate VI 2. Hydrogenation of intermediate VI to give intermediate V 3. Resolution of intermediate V to give intermediate IV with enantiomeric purity >99% 4. Release of intermediate IV in a basic medium to give intermediate III 5. N-acylation reaction of intermediate III to give II (tofacitinib) 6.
    Type: Grant
    Filed: April 7, 2016
    Date of Patent: November 28, 2017
    Assignee: OLON S.P.A.
    Inventors: Jacopo Bonanomi, Stella Defiore, Barbara Novo
  • Publication number: 20170174662
    Abstract: Disclosed are a novel crystalline form and an amorphous form of Olaparib, and the process for their preparation.
    Type: Application
    Filed: December 19, 2016
    Publication date: June 22, 2017
    Inventors: Barbara Novo, Jacopo Bonanomi, Stella Defiore, Francesco Calogero
  • Publication number: 20160297825
    Abstract: Disclosed is a novel process for the synthesis of tofacitinib citrate on an industrial scale with high yields and purity starting with cis-(1-benzyl-4-methyl-piperidin-3-yl)methylamine bis-hydrochloride racemate (intermediate VIII), which comprises: 1. Condensation between intermediates VII and VIII to give intermediate VI 2. Hydrogenation of intermediate VI to give intermediate V 3. Resolution of intermediate V to give intermediate IV with enantiomeric purity >99% 4. Release of intermediate IV in a basic medium to give intermediate III 5. N-acylation reaction of intermediate III to give II (tofacitinib) 6.
    Type: Application
    Filed: April 7, 2016
    Publication date: October 13, 2016
    Inventors: Jacopo Bonanomi, Stella Defiore, Barbara Novo